|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | HIV,HCV,and HBV Co-Infections in a Rural Area of Shanxi Province with a History of Commercial Blood Donation显示文摘Background:Unhygienic blood collection in the early 1990s led to blood‐borne infections in Central China.This study aimed to estimate human immunodeficiency virus (HIV) co‐infection with hepatitis C and B viruses (HCV and HBV) and their risk factors in a rural area of Shanxi Province with a history of commercial blood donation.Methods:A cross‐sectional study was conducted in 2004.All adult residents in the target area were invited to participate in the study.Face‐to‐face interviews were completed and blood specimens were tested for HIV,HCV,and HBV surface antigen (HBsAg).Results:Prevalence rates of HIV,HCV,and HBsAg were 1.3% (40/3 062),12.7% (389/3 062),and 3.5% (103/2982),respectively.Of the 40 HIV‐positive specimens,85% were HCV positive and 2.5% were HBsAg positive.The history of commercial blood donation was positively associated with HIV,HCV,and HIV/HCV co‐infections,but was negatively associated with HBsAg seropositivity.Migration for employment in the last 5 years was positively related to HIV,HBsAg,and HIV/HCV co‐infections.Univariate logistic analysis showed that illegal drug use,number of sex partners,extramarital sex behavior,commercial sex behavior,and condom use rate were not related to anti‐HIV,anti‐HCV,HBsAg seropositivity or their co‐infections.Conclusion:The history of commercial blood donation was the main risk factor for HIV,HCV,and HIV/HCV co‐infections in this former commercial blood donation area.HIV and HCV prevention and treatment interventions are important in this area. | DONG RuiLing QIAO Xiao Chun JIA WangQian WONG Michelle QIAN HanZhu ZHENG XiWen XING WenGe LAI ShengHan WU ZhengLai JIANG Yan WANG Ning | 2011 | Biomedical and Environmental Sciences2011，24，3： | 1 |
| 2 | Interscan reproducibility of quantitative coronary plaque volume and composition from CT coronary angiography using an automated method显示文摘 | Annika Schuhbaeck Damini Dey Yuka Otaki Piotr Slomka Brian G. Kral Stephan Achenbach Daniel S. Berman Elliott K. Fishman Shenghan Lai Hong Lai | 2014 | European Radiology2014，，： | 1 |
| 3 | Echocardiographic and pathologic characteristics of primary cardiac tumors: a study of 149 cases显示文摘 | Qingyi Meng Hong Lai Joao Lima Wenjing Tong Yuanyu Qian Shenghan Lai | 2002 | International Journal of Cardiology2002，，1： | 1 |
| 4 | Association study of genetic variants of 17 diabetes‐related genes/loci and cardiovascular risk and diabetic nephropathy in the C hinese S he population (中国畲族人群17个糖尿病相关基因位点的遗传变异与心血管风险和糖尿病肾病的相关性)显示文摘 | Gang Chen Yuan Xu Yinghua Lin Xiaolan Lai Jin Yao Baoying Huang Zichun Chen Huibin Huang Xianguo Fu Lixiang Lin Shenghan Lai Junping Wen | 2013 | Journal of Diabetes2013，，2： | 1 |
| 5 | Framingham公式在美国黑人青年无冠心病症状HIV感染吸毒患者中的临床应用价值显示文摘 | 杜捷夫 孟庆义 Hong Lai Shenghan Lai | 2006 | 心脏杂志2006，18，6： | 0 |
| 6 | What do we know about IL-6 in COVID-19 so far?显示文摘Interleukin 6(IL-6)is a cytokine with dual functions of pro-inflammation and anti-inflammation.It is mainly produced by mononuclear macrophages,Th2 cells,vascular endothelial cells and fibroblasts.IL-6 binds to glycoprotein 130 and one of these two receptors,membrane-bound IL-6R or soluble IL-6R,forming hexamer(IL-6/IL-6R/gp130),which then activates different signaling pathways(classical pathway,trans-signaling pathway)to exert dual immune-modulatory effects of anti-inflammation or pro-inflammation.Abnormal levels of IL-6 can cause multiple pathological reactions,including cytokine storm.Related clinical studies have found that IL-6 levels in severe COVID-19 patients were much higher than in healthy population.A large number of studies have shown that IL-6 can trigger a downstream cytokine storm in patients with COVID-19,resulting in lung damages,aggravating clinical symptoms and developing excessive inflammation and acute respiratory distress syndrome(ARDS).Monoclonal antibodies against IL-6 or IL-6R,such as tocilizumab,sarilumab,siltuximab and olokizumab may serve as therapeutic options for COVID-19 infection. | Jingrui Jiang Jun Wang Lulu Yao Shenghan Lai Xueji Zhang | 2021 | Biophysics Reports2021，7，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员